Back to Search
Start Over
Safety and efficacy study of lung cancer stem cell vaccine.
- Source :
-
Immunologic research [Immunol Res] 2015 May; Vol. 62 (1), pp. 16-22. - Publication Year :
- 2015
-
Abstract
- In this trial, lung cancer stem cells (CSCs) were separated and cultured to produce a vaccine; its safety and efficacy were prospectively evaluated in low-, medium-, and high-dose groups. Between February and September 2014, we enrolled 90 patients who met the enrollment criteria and assigned them to three groups (n = 30). Throughout the trial, injection site reaction was the most common reaction (63 %), and fever was least common (16 %); however, there was no difference among the three groups. When the immune responses pre- and post-vaccination were compared, we found that the CSC-nonspecific and CSC-specific responses were both significantly enhanced in the medium- and high-dose groups. This study is the first clinical trial of a lung CSC vaccine and preliminarily proves its safety and efficacy.
Details
- Language :
- English
- ISSN :
- 1559-0755
- Volume :
- 62
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Immunologic research
- Publication Type :
- Academic Journal
- Accession number :
- 25743632
- Full Text :
- https://doi.org/10.1007/s12026-015-8631-7